Your browser is no longer supported. Please, upgrade your browser.
Concert Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.98 Insider Own1.60% Shs Outstand34.09M Perf Week-6.34%
Market Cap117.27M Forward P/E- EPS next Y-2.79 Insider Trans-2.71% Shs Float30.62M Perf Month18.06%
Income-66.30M PEG- EPS next Q-0.61 Inst Own52.20% Short Float3.66% Perf Quarter-7.36%
Sales32.60M P/S3.60 EPS this Y27.20% Inst Trans-4.10% Short Ratio1.40 Perf Half Y-17.68%
Book/sh2.91 P/B1.17 EPS next Y-43.90% ROA-46.00% Target Price13.00 Perf Year-67.86%
Cash/sh3.08 P/C1.10 EPS next 5Y- ROE-56.80% 52W Range2.64 - 13.50 Perf YTD-73.10%
Dividend- P/FCF- EPS past 5Y-33.30% ROI-55.30% 52W High-74.81% Beta0.36
Dividend %- Quick Ratio9.40 Sales past 5Y-34.70% Gross Margin- 52W Low28.79% ATR0.24
Employees71 Current Ratio9.40 Sales Q/Q-66.70% Oper. Margin- RSI (14)44.55 Volatility4.68% 8.29%
OptionableYes Debt/Eq0.00 EPS Q/Q-30.60% Profit Margin- Rel Volume0.21 Prev Close3.41
ShortableYes LT Debt/Eq0.00 EarningsNov 09 BMO Payout- Avg Volume799.92K Price3.40
Recom1.80 SMA20-10.09% SMA503.25% SMA200-16.37% Volume167,676 Change-0.29%
Dec-16-20Initiated Berenberg Buy $25
Mar-30-20Initiated Jefferies Buy $23
Oct-03-19Reiterated H.C. Wainwright Buy $29 → $25
Jun-24-19Initiated SunTrust Buy $30
Jun-13-19Upgrade Janney Neutral → Buy
Jun-13-19Reiterated H.C. Wainwright Buy $26 → $29
Sep-13-18Initiated Janney Neutral
Mar-09-18Upgrade Mizuho Neutral → Buy $23 → $27
Jan-12-18Downgrade Mizuho Buy → Neutral $23
Oct-26-17Initiated Mizuho Buy $23
Jul-24-17Initiated H.C. Wainwright Buy $20
Mar-07-17Reiterated Stifel Buy $21 → $31
Jul-01-16Initiated Stifel Buy $23
Sep-22-15Reiterated ROTH Capital Buy $22 → $32
Aug-12-15Initiated Brean Capital Buy $21
Nov-12-14Reiterated ROTH Capital Buy $28 → $21
Mar-10-14Initiated UBS Buy $25
Nov-11-21 07:00AM  
Nov-09-21 03:30PM  
Nov-04-21 08:48AM  
Nov-02-21 07:00AM  
Oct-28-21 03:05PM  
Oct-25-21 07:00AM  
Sep-22-21 06:53AM  
Sep-03-21 07:00AM  
Aug-31-21 07:00AM  
Aug-05-21 04:30PM  
Jul-29-21 03:04PM  
Jul-24-21 04:18AM  
Jul-01-21 01:44PM  
May-28-21 08:58AM  
May-27-21 07:00AM  
May-26-21 07:00AM  
May-25-21 02:50AM  
May-18-21 06:43AM  
May-17-21 04:01PM  
May-04-21 01:00PM  
Apr-27-21 07:00AM  
Apr-22-21 12:33PM  
Mar-02-21 07:00AM  
Feb-25-21 03:30PM  
Feb-24-21 02:38AM  
Feb-18-21 07:00AM  
Feb-01-21 03:47PM  
Dec-30-20 09:00AM  
Dec-17-20 01:25PM  
Dec-16-20 12:02AM  
Nov-09-20 07:00AM  
Nov-06-20 04:01PM  
Nov-05-20 06:30AM  
Nov-03-20 07:00AM  
Nov-01-20 08:57AM  
Oct-29-20 10:00AM  
Oct-22-20 07:00AM  
Oct-13-20 07:00AM  
Sep-29-20 07:00AM  
Sep-08-20 07:00AM  
Aug-18-20 06:00AM  
Aug-12-20 08:06AM  
Aug-06-20 11:05AM  
Jul-30-20 12:33PM  
Jul-08-20 07:00AM  
Jul-06-20 11:44AM  
Jun-30-20 12:00PM  
Jun-24-20 10:39AM  
Jun-12-20 04:01PM  
May-26-20 07:00AM  
May-22-20 08:52AM  
May-12-20 09:14PM  
May-01-20 12:30AM  
Apr-30-20 08:45AM  
Apr-29-20 12:00PM  
Apr-23-20 07:00AM  
Apr-15-20 08:55AM  
Apr-01-20 07:00AM  
Mar-26-20 11:54AM  
Mar-12-20 12:13AM  
Feb-24-20 07:00AM  
Feb-20-20 07:00AM  
Jan-30-20 04:01PM  
Jan-28-20 09:00AM  
Jan-27-20 04:02PM  
Jan-24-20 05:52AM  
Jan-22-20 08:40AM  
Dec-19-19 04:05PM  
Dec-16-19 05:54AM  
Dec-13-19 02:18PM  
Dec-02-19 07:00AM  
Nov-25-19 11:21PM  
Nov-12-19 07:00AM  
Nov-10-19 08:40AM  
Nov-07-19 08:15AM  
Nov-06-19 07:00AM  
Nov-05-19 01:36PM  
Oct-31-19 10:35AM  
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Becker Marc A.Chief Financial OfficerAug 16Sale3.287,30423,95764,067Aug 17 04:01 PM
Cassella James VChief Development OfficerAug 16Sale3.288,08626,52285,978Aug 17 04:02 PM
Tung Roger DChief Executive OfficerFeb 17Sale7.2013,48097,056808,578Feb 17 09:42 PM
Stuart NancyChief Operating OfficerFeb 16Sale7.326,04944,279173,280Feb 17 09:34 PM
Munsie Jeffrey AChief Legal OfficerFeb 16Sale7.323,76327,54546,153Feb 17 09:31 PM
Cassella James VChief Development OfficerFeb 16Sale7.323,76327,54594,064Feb 17 09:27 PM
Becker Marc A.Chief Financial OfficerFeb 16Sale7.323,76327,54571,371Feb 17 09:21 PM